A Phase 2a/2b Double-Blind, Randomized, Placebo-Controlled Study Assessing Efficacy, Safety, and Dose-Response of Vatelizumab in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS)

Trial Profile

A Phase 2a/2b Double-Blind, Randomized, Placebo-Controlled Study Assessing Efficacy, Safety, and Dose-Response of Vatelizumab in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS)

Discontinued
Phase of Trial: Phase II

Latest Information Update: 11 Feb 2017

At a glance

  • Drugs Vatelizumab (Primary)
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Acronyms EMPIRE
  • Sponsors Sanofi Genzyme
  • Most Recent Events

    • 12 Jul 2016 Status changed from active, no longer recruiting to discontinued based on planned interim analysis of the primary endpoint. Not linked to any safety concern
    • 27 Apr 2016 Planned End Date changed from 1 Mar 2016 to 1 Aug 2017.
    • 22 Dec 2015 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top